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Randomized controlled trials for antipsychotic drugs have
a variety of design features suited to diverse purposes. Ef-
ficacy (or explanatory) trials seek to establish if a drug can
reduce psychotic symptoms under ideal circumstances. To
isolate drug effects, researchers enroll carefully selected
patients. Specialized research personnel use rating scales
of symptoms that are sensitive to drug effects as the study
primary outcomes. Large simple trials (LSTs) are con-
ducted at typical treatment settings with usual clinical per-
sonnel and enroll large numbers of participants so small but
clinically important differences between treatment options
can be detected. LSTs focus narrowly on clearly defined,
patient-oriented outcomes. To some extent, practical trials
can be conceptualized as hybrids of efficacy and large sim-
ple trials. Practical trials provide independent evidence to
inform decision makers about the everyday effectiveness of
clinically relevant alternative interventions. Practical trial
researchers include a heterogeneous population of patients
and collect data on a broad range of meaningful health out-
comes at many types of practice settings intended to rep-
resent usual treatment. The designers of practical trials
make trade-offs between internal validity, external valid-
ity, the breadth of issues addressed, and the ability to detect
small differences. The different objectives of trials should
be considered in the interpretation of the complete body of
randomized evidence on antipsychotic drugs.
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Introduction
Randomized controlled trials (RCTs) remain the gold
standard for establishing evidence to support clinical and
policy choices. RCTs comparing antipsychotic drugs,
however, have produced conflicting results and interpre-
tations,1–3 and many studies have been criticized for fail-
ing to address critical issues adequately.4–6 This article
aims to delineate the features of certain kinds of RCTs
relevant to antipsychotic treatment of schizophrenia
and to demonstrate that diverse trials may have comple-
mentary purposes that together can provide a broad un-
derstanding of antipsychotic drug effects.
Efficacy or explanatory trials are usually conducted by
a drug’s developer to meet requirements for marketing
approval by drug regulatory agencies. These highly stan-
dardized, short-term studies compare a new drug with
placebo or an active comparator or both and usually
make no pretenses about a drug’s long-term effectiveness.
Safety, efficacy, and speed are critical priorities because
companies seek rapid approval for a new drug.
Large simple trials (LSTs) are new for antipsychotic
drugs and psychiatry but are widely used in other medical
fields.Thesetrialsenrollgreatnumbersofpatientsattypical
practice settings and randomly assign treatments, but use
few specialized research procedures and collect only mini-
mal data focused on a critical outcome. Prominent LSTs in
cardiology, eg, the Clopidogrel and Metoprolol in Myocar-
dial Infarction Trial (COMMIT)7,8 and Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack
Trial (ALLHAT)9 investigations, used mortality or stroke
as primary outcomes. These influential studies have
helped determine the relative benefits and risks of treat-
ments for hypertension and acute myocardial infarction.
Practical or pragmatic trials are also relatively new to
psychiatry, but several examples, including the recent
Clinical Antipsychotic Trials of Intervention Effectiveness
(CATIE),10–14 Rapid Tranquilization Clinical Trial
(TREC),15–17 and Cost Utility of the Latest Antipsychotic
Drugs in Schizophrenia Study (CUtLASS)18,19 investiga-
tions, have provided additional information about the
relative risks and benefits of antipsychotic drugs. Practi-
cal trial designs can vary considerably in their complex-
ity, but their overall goal is to provide comparative
treatment information that can be applied broadly to rel-
evant patients.
In this article, we describe the typical characteristics and
goals of efficacy trials, LSTs, and practical trials and then
use contemporary examples involving antipsychotic drugs
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to illustrate the merits, weaknesses, and what can be
learned from each type of trial. Table 1 shows typical char-
acteristics of these trials and Table 2 provides examples.
Efficacy Trials: Can a Drug Work?
Efficacy (or explanatory) trials seek to establish if a drug
can work under ideal circumstances.20 Developers of new
antipsychotic drugs use efficacy trials to establish a drug’s
capacity to reduce psychotic symptoms. The major goals
in the design of efficacy trials is to make sure that any
treatment effect is likely to be picked up and to reduce
the background ‘‘noise’’ caused particularly by interrater
variation in the assessment of outcomes and the presence
of comorbidity, ie, to maximize the signal-to-noise ratio.
To achieve these aims, researchers conduct these studies
in specialized settings using trained personnel and
deploying rating scales of symptoms that are sensitive
to drug effects as the study primary outcomes.20 A pur-
ported antipsychotic is commonly compared both with
placebo and with a known antipsychotic; this procedure
helps to confirm ‘‘assay sensitivity’’, or that the study de-
sign and procedures are adequate to detect a difference
between a drug known to be effective and placebo.21
Trained research personnel recruit patients experiencing
an acute episode of schizophrenia and conduct specialized
assessments to ensure that diagnostic and severity of
illness criteria are met. Most individuals with medical ill-
nesses, substance use disorders, or additional psychiatric
diagnoses are excluded both to reduce the likelihood of
Table1. TypicalCharacteristics ofEfficacy,LargeSimple, andPracticalTrials (Adaptedfrom StroupS.EpidemiologiaePsichiatriaSociale,
vol 14, no 3, 2005)
Efficacy Trials Large Simple Trials Practical Trials
Goal Achieve regulatory approval
to market drug
Compare treatment options to
examine small but potentially
important differences
To inform decision makers about
clinical and policy choices
Specific Aims To establish short-term





To examine relative benefits and
risks of available treatments
Primary outcome Improvement of target
symptoms
A discrete and clinically
meaningful outcome
A discrete and clinically
meaningful outcome
Secondary outcomes Safety measures; response
rates
Few, if any Many health-related
outcomes
When conducted Before a drug is marketed Postmarket Postmarket
Sponsor Drug maker Varies; drug maker,
government agency,
foundation
Varies; drug maker, government
agency, foundation






Sample size A few hundred Thousands Hundreds to thousands
Comparisons Placebo and an active
comparator
One or more active
comparators; clinical
equipoise
One or more active
comparators; clinical equipoise
Dosing Fixed dosing Flexible dosing in clinically
used range
Flexible dosing in clinically used
range
Blinding Double blinded Open label, single, or double
blinded
Open label, single, or
double blinded
Duration 6 Weeks 1 Year or longer 1 Year or longer





Sites are typical treatment
settings: often hundreds
of sites
Sites are typical treatment
settings, may need capacity to
measure many outcomes: often
hundreds of sites




Protocol very similar to usual
practice; minimal additional
assessments or procedures
Protocol designed to mimic usual






Excluded to isolate the
effects of the drug
Included except for specific
contraindications to examine
effects in typical patient
populations
Included except for specific
contraindications to examine






drugs for limited time
Allowed as in usual practice Allowed as in usual practice;
some exclusions depending
on study aims
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serious adverse events and limit the variance in out-
comes. To protect against ascertainment and perfor-
mance biases, treatments are assigned randomly under
double-blind conditions, so that neither the patient nor
the research team providing clinical care and conducting
outcome assessments know the treatment assignment.
Typical efficacy trials are designed to follow the clinical
course of participants for 6–8 weeks. Trained personnel
conduct frequent assessments of symptoms and side
effects using psychometrically validated instruments.
The primary outcome is typically improvement on
a symptom rating scale, such as the Positive and Negative
Syndrome Scale (PANSS). Response, or improvement by
some prespecified amount on a symptom rating scale, is
a common secondary outcome. Known side effects and
common laboratory parameters are measured systemat-
ically, while other adverse events are reported spontane-
ously if and when they occur.
Efficacy trials efficiently meet the requirements of
drug-licensing agencies to show that a drug works and
that it is safe to use. They work well for drug developers
that want to complete trials rapidly, because the high
costs of using many highly trained and geographically
dispersed research centers can be offset against the re-
duced time to market and profitability. However, efficacy
trials do not reveal much about how a new drug works in
typical settings, with patients who may have medical and
psychiatric comorbidities and who may take other med-
ications. They do not tell us about long-term safety issues
or about the effects of drug therapies on mortality, ability
to work, or other issues that are important to patients.
Example of an Efficacy (or Explanatory) Trial
‘‘Efficacy and safety of paliperidone extended-release
tablets: results of a 6-week, randomized, placebo-
controlled study’’ is a recent, typical example of an
Table 2. Actual Characteristics of Representative Efficacy Large Simple and Practical Trials
Efficacy Trials Large Simple Trials Practical Trials
Example Phase 3 US paliperidone trial22 ZODIAC37 CATIE38
Goal Achieve regulatory approval
to market paliperidone
Examine safety issue raised in
premarketing studies
To inform decision makers
about relative effectiveness of
antipsychotic drugs
Specific Aims To determine short-term
efficacy and safety of
paliperidone
To determine long-term safety
of ziprasidone
To examine relative benefits and
risks of widely used
antipsychotics
Primary outcome Change in PANSS total score 1 Year nonsuicide mortality Time to treatment discontinuation
for any cause
Secondary outcomes Many safety parameters;
other clinical parameters






outcomes, including safety, costs,
quality of life, and neurocognitive
function
When conducted Before marketing Postmarket Postmarket
Sponsor Janssen Pfizer NIMH
Diagnostic criteria Diagnosis by structured
interview
Clinical diagnosis Diagnosis by structured interview
Sample size 444 >18 000 1493
Comparisons Paliperidone 6 or 12 mg
daily vs olanzapine 10 mg
daily vs placebo
Ziprasidone vs olanzapine Olanzapine vs perphenazine vs
quetiapine vs risperidone
vs ziprasidone
Dosing Fixed dosing Flexible dosing in clinically
used range
Flexible dosing in clinically
used range
Blinding Double blinded Open label Double blinded
Duration 6 Weeks 1 Year for primary outcome 18 Months
Research sites 74 Research sites with inpatient
services in the United States
Almost 1000 sites in 18
countries: sites are typical
treatment settings
57 sites in United States: Typical
treatment settings capable of
implementing detailed
research protocol
Research protocol Strictly defined research protocol
with frequent research
assessments and procedures
Protocol very similar to usual
practice; minimal additional
assessments or procedures
Protocol designed to mimic








Included except for specific
contraindications






Allowed as in usual practice Allowed as in usual practice;
other antipsychotics prohibited
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efficacy trial.22 Janssen (Titusville, NJ) conducted this
phase 3 trial to meet regulatory requirements for
approval of paliperidone as a treatment for acute
schizophrenia. The trial compared 2 fixed dosages of
paliperidone (6 and 12 mg daily) with placebo and olan-
zapine 10 mg daily for up to 6 weeks under double-blind
conditions. Change in symptoms as measured by the
PANSS total score was the primary outcome. Clinical re-
sponse was defined as a 30% reduction in PANSS total
score.
Eligibility
Individuals aged 18 or older who were experiencing an
acute episode of schizophrenia as indicated by a PANSS
score of 70–120 (representing moderate to severe, but not
mild or extremely severe, psychopathology) were eligi-
ble.22 Patients met DSM-IV criteria for schizophrenia
and agreed to at least 14 days of hospitalization. Exten-
sive exclusion criteria included the following: substance
dependence in the previous 6 months; medical conditions
that might affect drug pharmacokinetics; history of tar-
dive dyskinesia or neuroleptic malignant syndrome; sig-
nificant risk of suicide or violence; female patients who
were pregnant or breast feeding; use of antidepressants
or mood stabilizers within 2 weeks of screening; history
of any drug sensitivity or hypersensitivity to olanzapine,
risperidone, or paliperidone; or a history of unrespon-
siveness to antipsychotic drugs.
Study Conduct
Researchers at 74 sites with inpatient units in the United
States conducted the study.22 They randomly assigned
a total of 444 volunteer patients to one of the 4 ‘‘treat-
ment’’ arms. Previous medications, including antipsy-
chotics, antiparkinsonian agents, and beta-blockers were
discontinued 3 days before randomization. Patients
were assigned to take either paliperidone 6 mg, paliper-
idone 12 mg, olanzapine 10 mg, or placebo once daily in
the morning for 6 weeks. Participants were hospitalized
for the first 14 days and assessed at least weekly through-
out the trial. Trained raters assessed drug efficacy using
multiple measures, including the PANSS, the Clinical
Global Impression (CGI) scale, and the Personal and
Social Performance (PSP) scale. The study included mul-
tiple safety measures, including laboratory evaluations,
physical parameters, and rating scales of neurologic
side effects.
The primary efficacy analysis was conducted among
randomized patients who received at least one dose of
medicine and had at least one post-baseline observa-
tion.22 The Last Observation Carried Forward (LOCF)
method was used to deal with missing data for partici-
pants who left the study early. Safety was evaluated
among all patients who took at least one dose of
double-blinded medication.
Outcomes
Of the 444 people randomized, fewer than half of partic-
ipants in any of the groups completed the 6-week trial
(placebo 34%, paliperidone 6 mg 46%, paliperidone
12 mg 48%, and olanzapine 10 mg 45%).22 In the primary
report from this study, the authors presented efficacy
data only for paliperidone and placebo. They excluded
olanzapine from the primary efficacy analyses because
it had been included only for assay sensitivity. Neverthe-
less, they reported safety outcomes for all treatment arms
for the PSP and for many safety measures, including
treatment-emergent adverse events.
Using LOCF analyses, the authors reported that both
doses of paliperidone were more efficacious than placebo
in reducing symptoms measured by the PANSS and that
patients taking paliperidone were significantly more
likely to meet response criteria.22 Adverse events rates
were high in all groups, including placebo and olanzapine
(range 73%–79%). Paliperidone was associated with ele-
vated prolactin levels and dose-related neurologic symp-
toms, although the specific effects on akathisia and on
sexual functioning that might be related to high prolactin
levels were not reported. The comparison to olanzapine
provided interesting information even though it was
included only for assay sensitivity. Overall, olanzapine
10 mg daily appeared to be similar in efficacy to both pal-
iperidone 6 and 12 mg daily, while olanzapine 10 mg
seemed to be associated with greater incidence of extra-
pyramidal side effects than paliperidone 6 mg but lower
incidence than paliperidone 12 mg.
Limitations of This Efficacy Trial
Although the low rate of study completion (no study arm
with 50% completion rates at 6 weeks) may reflect inves-
tigator attitudes about placebo-controlled studies and
a desire to minimize the risks to study participants, the
huge amount of missing data makes it very difficult to
make inferences even about the short-term effects of
the drug. An extremely cautious observer might decide
the study is inconclusive because less than half of the peo-
ple who took paliperidone continued to do so for the
scheduled 6 weeks of the study. A less conservative inter-
pretation is that that paliperidone appeared better than
a placebo for reducing schizophrenic symptoms over
a few weeks. Assessment of long-term risks and benefits
were not goals of this trial.
Large Simple Trials: Are There Small but Important
Differences Between Available Treatments?
LSTs focus narrowly on clearly defined, patient-oriented
outcomes.21 A typical LST outcome, mortality, is discrete
and meaningful. Designers of LSTs resist the desire to
collect information on a wide array of outcomes, instead
using resources to enroll large numbers of participants so
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they can meaningfully detect relatively small but clini-
cally important differences.20 LSTs are conducted at typ-
ical treatment settings with usual clinical personnel.
Study procedures are simple so that the need for special-
ized research training and interference with routine clin-
ical care is minimized. Inclusion criteria are broad, and
exclusion criteria are minimal. The key criterion for study
entry is uncertainty about which treatment option is best
for the individual participant. Treatments are randomly
assigned to avoid selection bias.
Example of a Large Simple Trial
There are no excellent examples of LSTs involving anti-
psychotic drugs that have been completed and fully
reported. Although the results are not yet available,
the best available example is the Ziprasidone Observa-
tional Study of Cardiac Outcomes (ZODIAC) trial,
which was conducted by Pfizer to satisfy regulatory agen-
cies that wanted to know about the long-term effects
of the new drug on mortality.23 Premarketing studies
revealed that ziprasidone was associated with prolonga-
tion of the electrocardiographic QT interval, which
carried a potential increased risk of fatal ventricular
arrhythmias. Because even a small increase in mortality
would be clinically important, an LST designed to detect
effects on mortality was highly appropriate.
Eligibility
Individuals aged 18 or older who were diagnosed with
schizophrenia and whose psychiatrist wanted to start
a new antipsychotic and would consider either olanzapine
or ziprasidone were eligible to participate.23 Exclusion cri-
teria were minimal as follows: pregnant or lactating
women, presence of disease with life expectancy less
than 1 year, and participation in any study involving inves-
tigational products within 30 days of entering the study.
Study Conduct
Researchers at almost 1000 sites in 18 countries con-
ducted the study.23 They randomly assigned more than
18 000 volunteer patients to receive open-label olanzapine
or ziprasidone. No other study-related interventions, no
laboratory testing, or clinical monitoring was required.
Minimal data collected at baseline included only the fol-
lowing: demographics, the CGI scale to indicate the sever-
ity of illness, cardiac risk factors, and prior antipsychotic
use. Simple outcome information, including vital status,
data on continuation of the assigned drug, hospitaliza-
tions, and emergency room visits, was obtained from
the treating physician or other member of the clinical
team at regular intervals. If hospitalization occurred,
then the hospital records were obtained. Each participant
was intended to be followed for 1 year regardless of treat-
ment status. An ‘‘Endpoint Committee’’ that was blinded
to treatment assignments adjudicated the endpoints
based on all available information.
Results
When the results of the ZODIAC study are available,
they will provide important information about mortality
associated with both ziprasidone and olanzapine over
1 year of treatment.
Limitations of This LST
Like other LSTs, ZODIAC will provide important data
on an important, highly focused research question. The
study will provide critical information about the relative
risk of death among a broad group of patients treated
with either olanzapine or ziprasidone. Because ziprasi-
done is widely promoted and used among individuals
with significant risk factors for cardiovascular disease,
its effects on mortality are important. Olanzapine is a
reasonable comparator because it too is associated
with risk factors for cardiovascular disease, although
some observers may have preferred comparing ziprasi-
done to a drug not so strongly associated with risk factors
for heart disease. Secondary outcomes, including hospi-
talization rates and discontinuation of the assigned study
medication, will provide limited information for those
who want to know more about the relative effectiveness
of these 2 drugs. The ZODIAC study nicely illustrates the
trade-offs of a LST—many subjects are enrolled to
answer an important, focused question but many other
relevant health outcomes are unaddressed. The need to
enroll large numbers of participants means that results
of LSTs are often not quickly available. For example,
the results of the ZODIAC trial, which enrolled more
than 18 000 patients and examined relatively long-term
outcomes, were still not available several years after
the study question was identified and the trial begun.
Practical Trials: How Do Available Treatments
Compare Overall in Clinical Practice?
Practical trials are intended to provide independent evi-
dence to inform decision makers about clinical and policy
choices related to the risks and benefits of approved treat-
ments.24 Researchers design practical trials to provide
high-quality evidence, with high internal and external
validity, regarding the everyday effectiveness of clinically
relevant alternative interventions.24 To do this, research-
ers include a heterogeneous population of patients and
collect data on a broad range of meaningful health out-
comes at many types of practice settings intended to rep-
resent usual treatment.24
Practical trials use broad subject inclusion criteria and
minimal exclusion criteria to enhance external validity
and thus enhance the believability of study results for
clinicians and patients in typical treatment settings.25
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Practical trials compare treatments about which there is
clinical uncertainty about the outcome at the individual
patient level and use randomization to protect against se-
lection biases.26 Not all practical trials conceal the treat-
ment assignment from patients and study clinicians, but
for subjective outcomes determined by raters blinding of
the raters is necessary. The training and personnel
requirements of rater blinding place burdens on sites
that make it less likely that typical clinical sites, rather
than research sites, can participate in these trials. In ad-
dition, a desire to examine ‘‘a broad range of meaningful
health outcomes’’ often including service utilization to al-
low estimation of cost-effectiveness is at variance with
a desire to limit participant and researcher burden. To
some extent, practical trials can be conceptualized as
hybrids of efficacy and LSTs with the main trade-offs be-
ing in internal validity and the potential for a low signal-
to-noise ratio.
Example of a Practical (or Pragmatic) Trial
The US National Institute of Mental Health (NIMH) ini-
tiated the CATIE schizophrenia trial to provide objective
information about the long-term effectiveness and cost-
effectiveness of antipsychotic drugs in widespread use.10,14
The NIMH supported the study because it had a strong
interest in informing policy makers regarding the appro-
priate use of these commonly used, expensive, and some-
times toxic medications.27
The CATIE schizophrenia trial was a hybrid study that
included characteristics of efficacy trials and LSTs to
examine the overall effectiveness of antipsychotic drugs
for chronic schizophrenia.14 Researchers conducted the
study at heterogeneous practice settings, enrolled a rela-
tively large sample of participants, used a discrete primary
end point, and attempted to mimic routine clinical practi-
ces. However, because CATIE also included double blind-
ing and an extensive array of assessments, many of which
required trained clinical raters, all participating clinical
sites were required to have specialized research personnel.
Eligibility
Individuals aged 18–65 years with a diagnosis of schizo-
phrenia and who were appropriate for treatment with an
oral antipsychotic medication were eligible to enroll
in the CATIE schizophrenia trial.14 Exclusion criteria
were as follows: diagnosis of schizoaffective disorder,
mental retardation, or other cognitive disorders; history
of serious adverse reactions to any of the proposed treat-
ments; patients having a first schizophrenic episode;
patients with persistent severe symptoms despite an ade-
quate trial of one of the proposed treatments, prior treat-
ment with clozapine for treatment resistance; current
pregnancy or breast-feeding; and serious and unstable
medical conditions. People with medical conditions
that were not serious and unstable, and people with sub-
stance use disorders, were included.
Study Conduct
The CATIE schizophrenia trial was conducted at 57 clin-
ical sites representing the array of clinical settings where
people with schizophrenia receive treatment in the United
States.10 The study enrolled nearly 1500 participants and
randomly assigned them to receive olanzapine, perphena-
zine, quetiapine, risperidone, or ziprasidone under
double-blind conditions.14 Patients had monthly study
visits. Medications were dosed flexibly and, except for
additional antipsychotic agents, other medications
were permitted throughout the trial. Patients continued
on this first treatment for 18 months or until treatment
was discontinued for any reason (phase 1).
Participants who did not respond to or tolerate the first
assigned medication could enter subsequent phases of the
trial. If the phase 1 treatment was perphenazine, patients
then received randomized, double-blinded treatment with
a second-generation antipsychotic (phase 1B).14 If patients
in phase 1B again discontinued treatment, then they
entered phase 2. In phase 2, patients could choose between
2 randomization pathways. An ‘‘efficacy’’ pathway (phase
2E) was recommended to individuals who discontinued
the previous treatment due to inadequate symptom relief.
A ‘‘tolerability’’ pathway (phase 2T) was recommended to
individuals who discontinued the previous treatment due
to intolerability. If study participants discontinued either
of the phase 2 studies they could enter phase 3, which
allowed open choice of one of 9 treatment options.
The CATIE investigators selected time until all-cause
treatment discontinuation, meant to reflect the overall
effectiveness and acceptability of the medications, as
the primary outcome.14,28 They chose medication discon-
tinuation because it integrates patient and clinician judg-
ments of efficacy, safety, and tolerability into a discrete,
global measure of effectiveness. In addition, treatment
discontinuation conceptualized as evidence of ineffective-
ness avoids the problem of missing data by framing the
outcome so that missing data are actually part of the out-
come.21 Secondary outcomes included the reason for
treatment discontinuation and changes in PANSS and
CGI scores.14 Safety and tolerability outcomes included
adverse events, changes in weight, measures of neurologic
side effects, and laboratory analyses of parameters re-
lated to lipid and glucose metabolism. Other important
outcomes included effects of the drugs on psychosocial
and neurocognitive functioning. Health services use
was carefully tracked to allow comparison of the cost-
effectiveness of the study medicines.
Results
Almost 1500 individuals with schizophrenia volunteered
for the study and took randomly assigned medication.10
Only a minority of patients in each group remained on
the first assigned drug treatment for the 18-month dura-
tion of the study (18%–36%). The time to treatment
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discontinuation for all causes was longest with olanza-
pine compared with quetiapine and risperidone. The
comparisons of olanzapine with perphenazine and zipra-
sidone produced similar results but did not reach statis-
tical significance. Substantial increases in weight and
adverse metabolic changes associated with increased
risk of coronary heart disease were most common with
olanzapine.
Analyses of neurocognitive functioning found small
but significant improvements for all treatment groups,
but no difference among them after 2 months of treat-
ment.29 Similarly, modest improvements in psychosocial
functioning were evident across all treatment groups, but
there were no significant differences between treatment
groups.30 Cost-effectiveness analyses also found modest
improvement for all groups on several measures of effec-
tiveness over 18 months, but no significant differences
between perphenazine and any second-generation anti-
psychotic.31 Because total monthly health care costs
were lower for perphenazine than for second-generation
antipsychotics due to lower antipsychotic drug costs, the
investigators concluded that initiating treatment with
perphenazine was less costly and no less effective than ini-
tiating treatment with each of the 4 newer medications.31
In phases 1B, 2E, and 2T, outcomes for individuals
taking the various drugs depended considerably upon
clinical factors.11–13 The CATIE researchers concluded
that clinical circumstances affect drug effectiveness and
that these circumstances should be considered when
making drug choices.
Limitations of CATIE
The attempt to satisfy many constituencies by collecting
data on many outcomes and to include many treatment
arms and randomizations addressing a variety of clinical
situations meant that the study design was quite compli-
cated and required trained personnel. Decisions to add
ziprasidone to the protocol after recruitment began and
to use perphenazine in only one randomized phase of the
study generated controversy. The exclusion of people
with tardive dyskinesia from possible randomization
to perphenazine may have limited the study’s ability
to detect differences between perphenazine and the new-
er drugs. The decision to use double-blinded treatments
decreased the risk of measurement bias and improved
the study’s internal validity. However, double blinding
increased study costs, decreased the resemblance of the
study procedures to those of routine clinical care, and
tied the study to relative dose equivalences that have
proven controversial. These complexities and its large
size made the study expensive, at least compared
with other studies not conducted by pharmaceutical
companies.
Some aspects of routine clinical practice that were in-
corporated into the trial design in order to mimic usual
care led to problems interpreting the results and to
new information regarding the treatments. For example,
because patients entering the study could be randomized
to stay on their current treatment and there were
different rates of medication use at study entry, the study
provided new information about ‘‘switching’’.32 The
researchers found that switching medications affected
the primary outcome and that the effect of switching
varied according to both the drug being stopped and
the one being started.10,32 Another ‘‘naturalistic’’ aspect
of the study, which allowed choice between 2 pathways
in phase 2, provided information about patient and
clinician preferences but led to small numbers of
subjects and low statistical power in the efficacy
(clozapine) pathway.
Conclusions
RCTs, with the critical feature of randomization to
protect against selection biases, can be the source of
high-quality evidence to guide various kinds of
health-related decisions. In this article, we discussed
some types of late phase trials that can be of use to clini-
cians and other types of decision makers. We have not
included a discussion of all types of RCTs, eg, phase 2
or proof of concept studies, which may focus on dose
determination or mechanism of action rather than
efficacy.
The goals of a study can help guide decisions regarding
appropriate study designs and associated trade-offs.
Explanatory or efficacy trials provide ritualized, system-
atic data regarding the short-term efficacy and safety of
new drugs; they provide critical information about
how a drug can work in ideal circumstances but provide
little information regarding how it might work in
usual treatment settings. LSTs can provide definitive
answers to a focused clinical question regarding the com-
parative effects of treatments; the results have tremen-
dous external validity because the studies are
conducted in actual treatment settings using routine clin-
ical procedures. If researchers can create effective collab-
orations with clinicians, these enormous studies can be
conducted efficiently and cost-effectively. Although
LSTs can answer a focused question definitively, they
do not answer the multitude of other health-related ques-
tions that might be associated with antipsychotic drugs.
Practical trials can provide data regarding many health-
related outcomes, but because much data are collected
and study logistics are not simple, high costs can limit
the numbers of participants studied and may lead to
less than definitive results. Practical trials can provide
vast amounts of useful information, but designers of
these studies must resist the temptation to address all
the questions that might be asked regarding a treatment
in order to provide optimal information about the most
important issues.
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The thorough assessment of any health technology, in-
cluding pharmaceuticals, should include a systematic ap-
praisal of all the available randomized evidence. The
confidence that we can have that a drug is likely to be
effective in the real world will be increased if a treatment
effect found in practical trials is comparable to that ob-
served in highly controlled efficacy trials. For example,
the treatment effect on cognition observed in the large
pragmatic AD2000 trial comparing donepezil with pla-
cebo33 was comparable to that estimated in the short-
term efficacy trials conducted by the manufacturer.34
However, what can we conclude when trials with differ-
ent design characteristics differ in their results? We would
argue that it cannot be concluded that the results from
one kind of trial are necessarily ‘‘true’’ and the results
from the other trials are ‘‘wrong’’. Rather, reasons for
the apparent heterogeneity between trials should be
sought by examining the clinical and design differences
between the trials. If the trials are judged reasonably sim-
ilar in terms of design and participants, meta-analysis
may be possible in which case it is simple enough to de-
termine whether the differences between trials are likely
to be real or simply due to the play of chance.
The reasons for any material differences between trials
can be assessed using meta-regression, a technique which
statistically compares the results of trials according to trial-
level characteristics.35 For example, a systematic review
of industry-sponsored trials of second-generation anti-
psychotics (SGA) compared with first-generation
antipsychotics (FGA) found a number of methodological
weaknesses in the trials, and, furthermore, a meta-regression
strongly suggested that the substantial statistical hetero-
geneity between trials could be explained by differences
in the dose of the FGA used in the trial.4 The use of
a higher dose of a FGA was more likely to produce a
result favoring a SGA. Although a subsequent meta-
analysis using different methods found partially differ-
ent results,36 the design of CATIE was informed by
the meta-regression findings on dose. CATIE largely
confirmed the conclusion that there were probably no
major differences between drugs selected from both
available FGAs and SGAs on a broad range of clinically
relevant outcomes and cost-effectiveness.10,29–31 This
example demonstrates the particular usefulness of prac-
tical trials in situations when there is substantial residual
uncertainty about the comparative effectiveness of drugs
even in the presence of a large body of efficacy trials.
The different objectives of efficacy and practical trials
should be considered in the interpretation of the com-
plete body of randomized evidence.
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